ICCC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	1 776.00
Vidutinė apimtis	7 173.00
Rinkos kapitalizacija	39.84M
EPS	$0 ( 2024-02-27 )
Kita pelno data	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.85
ATR14	$0.0390 (0.76%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-06	Tomsche David Scott	Buy	3 100	Common stock $0.10 per value per share
2023-06-28	Gathagan Bryan K.	Buy	15 000	Non-Qualified Stock Options (Right to buy)
2023-06-16	Gathagan Bryan K.	Buy	0
2023-03-14	Tomsche David Scott	Buy	100	Common Stock, $0.10 per value per share
2023-03-14	Tomsche David Scott	Buy	69	Common Stock, $0.10 per value per share

INSIDER POWER
100.00
Last 96 transactions
Buy: 315 997 \| Sell: 92 686

ImmuCell Corp Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SGBX	0.878
VTSI	0.858
CCBG	0.844
FULT	0.843
HAS	0.837
EBMT	0.831
AMSF	0.83
LSBK	0.825
AMTB	0.815
CFB	0.812

10 Labiausiai neigiamai susiję koreliacijos
TRMD	-0.803

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

ImmuCell Corp Finansinės ataskaitos

Annual	2023
Pajamos:	$17.47M
Bruto pelnas:	$3.87M (22.15 %)
EPS:	$-0.750

FY	2023
Pajamos:	$17.47M
Bruto pelnas:	$3.87M (22.15 %)
EPS:	$-0.750

FY	2022
Pajamos:	$18.57M
Bruto pelnas:	$7.65M (41.19 %)
EPS:	$-0.320

FY	2021
Pajamos:	$19.24M
Bruto pelnas:	$8.66M (44.98 %)
EPS:	$-0.0102

Financial Reports:

No articles found.

ImmuCell Corp

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.